solute carrier family 25 member 20
Zuletzt aktualisiert 26. Jul 2023
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der SLC25A20 gene provides instructions for making a protein called carnitine-acylcarnitine translocase (CACT). This protein is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acid oxidation takes place within mitochondria, which are the energy-producing centers in cells. A group of fats called long-chain fatty acids must be attached to a substance known as carnitine to enter mitochondria. Once these fatty acids are joined with carnitine, the CACT protein transports them into mitochondria. Carnitine is then removed from the long-chain fatty acid and transported back out of mitochondria by the CACT protein. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
Normal function
Der SLC25A20 gene provides instructions for making a protein called carnitine-acylcarnitine translocase (CACT). This protein is essential for fatty acid oxidation, a multistep process that breaks down (metabolizes) fats and converts them into energy. Fatty acid oxidation takes place within mitochondria, which are the energy-producing centers in cells. A group of fats called long-chain fatty acids must be attached to a substance known as carnitine to enter mitochondria. Once these fatty acids are joined with carnitine, the CACT protein transports them into mitochondria. Carnitine is then removed from the long-chain fatty acid and transported back out of mitochondria by the CACT protein. Fatty acids are a major source of energy for the heart and muscles. During periods of fasting, fatty acids are also an important energy source for the liver and other tissues.
Conditions referring to this gene or chromosome
Other names
CAC
CACT
carnitine-acylcarnitine carrier
carnitine/acylcarnitine translocase
MCAT_HUMAN
solute carrier family 25 (carnitine/acylcarnitine translocase), member 20
Related patient information and medicines

Patient information leaflet
Zystische Fibrose
What causes cystic fibrosis. Cystic fibrosis is a genetic disorder. A genetic disorder is one that can be passed on from your parents through your genes. This ... If you inherit only one cystic fibrosis gene, you are called a carrier. About 1 in 25 people in the UK of white European descent sind carriers of the cystic fibrosis gene. It is much less.

Patient information leaflet
Hämochromatose
Find out more here: [/health/haemochromatosis-leaflet](https://patient.info/health/haemochromatosis-leaflet) People with haemochromatosis haben inherited a faulty gene, which directs the body to absorb too much iron from what they eat and drink. Causes of haemochromatosis Haemochromatosis ist a genetic condition. Approximately 1.

Patient information leaflet
Polyzystische Nierenerkrankung
If symptoms and problems develop, they usually start in adulthood. Autosomal recessive polycystic kidney disease (ARPKD) This is a rare condition which affects about 1 in 20,000 people. Problems typically develop soon after birth. Although people with PKD often develop kidney failure (end-stage kidney disease) between ages 55 to 65 years, some.

Patient information leaflet
Planung, schwanger zu werden
Screening tests Pregn... Some women may wish to have the screening test before becoming pregnant, especially if their family origins make these diseases more likely. People from families originating from Africa, the Caribbean, Southeast Asia, Sardinia, Greece, Turkey or Cyprus are more likely to have one of these conditions or to be a carrier for.

Patient information leaflet
Duchenne-Muskeldystrophie
Genes are found on 'chromosomes', rather like houses on a street. The DMD gene is located on a chromosome called the X chromosome. Boys have one X chromosome and one Y chromosome; girls have two X chromosomes. DMD is inherited in a pattern called 'X-linked inheritance'. The DMD gene is 'carried' by women but does not usually cause problems in.

Patient information leaflet
Hereditäre Sphärozytose
Hereditary spherocytosis (HS) ist an inherited condition of red blood cells. The disease can be mild and go unrecognised in some people. In others there may be severe anaemia requiring regular blood transfusions. Some people with hereditary spherocytosis may be offered surgery to remove their spleen. This usually helps the condition, but increases.
Weiterführende Lektüre und Referenzen
- solute carrier family 25 member 20; MedlinePlus, National Library of Medicine.
- Costa C, Costa JM, Slama A, Boutron A, Vequaud C, Legrand A, Brivet M. Mutational spectrum and DNA-based prenatal diagnosis in carnitine-acylcarnitine translocase deficiency. Mol Genet Metab. 2003 Jan;78(1):68-73. doi: 10.1016/s1096-7192(02)00205-6.
- Galron D, Birk OS, Kazanovitz A, Moses SW, Hershkovitz E. Carnitine-acylcarnitine translocase deficiency: identification of a novel molecular defect in a Bedouin patient. J Inherit Metab Dis. 2004;27(2):267-73. doi: 10.1023/B:BOLI.0000028780.01670.61.
- Iacobazzi V, Invernizzi F, Baratta S, Pons R, Chung W, Garavaglia B, Dionisi-Vici C, Ribes A, Parini R, Huertas MD, Roldan S, Lauria G, Palmieri F, Taroni F. Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat. 2004 Oct;24(4):312-20. doi: 10.1002/humu.20085.
- Iacobazzi V, Pasquali M, Singh R, Matern D, Rinaldo P, Amat di San Filippo C, Palmieri F, Longo N. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A. 2004 Apr 15;126A(2):150-5. doi: 10.1002/ajmg.a.20573.
- Korman SH, Pitt JJ, Boneh A, Dweikat I, Zater M, Meiner V, Gutman A, Brivet M. A novel SLC25A20 splicing mutation in patients of different ethnic origin with neonatally lethal carnitine-acylcarnitine translocase (CACT) deficiency. Mol Genet Metab. 2006 Dec;89(4):332-8. doi: 10.1016/j.ymgme.2006.06.009. Epub 2006 Aug 17.
- Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet. 2006 May 15;142C(2):77-85. doi: 10.1002/ajmg.c.30087.
- Morales Corado JA, Lee CU, Enns GM. Carnitine-Acylcarnitine Translocase Deficiency. 2022 Jul 21. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK582032/
- Ramsay RR, Gandour RD, van der Leij FR. Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta. 2001 Mar 9;1546(1):21-43. doi: 10.1016/s0167-4838(01)00147-9.
- Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med. 2004 Oct-Dec;25(5-6):521-32. doi: 10.1016/j.mam.2004.06.007.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
26. Jul 2023 | Neueste Version
1 Nov 2010 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

